RETRANSMISSION: MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank
-
Third-ranked Pegula, Medvedev power into US Open third round
-
Trump floats renaming Strait of Hormuz as 'Trump Strait'
-
Davis-Woodhall a doubt for Ultimate Championship after car crash
-
Man City, Chelsea fuel record-breaking Premier League transfer window
-
Third-ranked Pegula powers into US Open third round
-
Balogun rejected Everton move over transfer 'treatment'
-
Uber says laying off 'about 10%' of workforce worldwide
-
Northampton seek 'happy medium' in bid to keep England star Pollock
-
US judge rejects bid to break up Google's ad business
-
US energy secretary in Venezuela to sign Trump's 'biggest' oil deal
-
Rupert Murdoch 'very happy' to be played by Guy Pearce in new film
-
Branagh takes on action role in Apple's Cold War comedy 'Mayday'
-
Wall Street stocks rise despite bond yields, oil rising
-
Lawson fills in again for injured Hadjar at Monza
-
Brennan claims third Vuelta victory in stage 11 sprint
-
England omit Carse from squad for third Test against Pakistan
-
Nepal flood survivors cling to zipline to cross treacherous river
-
Venice festival gets underway with Clooney taking swipe at US government
-
US Treasury issues $1 coin with Trump's face on it
-
DNA tests and funerals in Nepal, a week after deadly floods
-
Fernandez 'didn't hesitate' over record Man City move
-
Iran threatens tougher strategy after US strikes kill 4 at wedding
-
Dutch shift 86 tonnes of gold from US, Canada to UK
-
Chevron unveils deal to double Venezuela venture output in 5 years
-
Nepal floods should mobilise climate action: UN green fund chief
-
Uganda names its oil 'Pearl Sweet' as it prepares for first exports
-
Nvidia boss presses G20 ministers to build AI infrastructure
-
Tiger Woods driver's license suspended for five years after crash
-
Liminal Launches Liminal Prime for Institutional OTC and Stablecoin Liquidity
-
Germany probes latest sabotage attacks on power grid
-
10 missing as cargo ship sinks after collision off Istanbul
-
Wall Street stocks mixed as energy prices, bond yields turn lower
-
30 years on, 'Tomb Raider' reboot sees Lara Croft through a 'modern lens'
-
Tiger Woods pleads guilty to reckless driving, license suspended
-
King Charles, Macron to view Bayeux Tapestry as French leader starts UK visit
-
Missing passengers likely went down with sunken ferry: N.Cyprus official
-
George Clooney says US run by 'least qualified people'
-
Premier League clubs splash cash to smash transfer record
-
China's Xi urges against Mideast interference in rare Egypt visit
-
Melting glaciers an 'immediate' climate risk: author of UN report
-
Venice to roll out red carpet for 'lucky' Clooney on opening night
-
Folarin Balogun's move to Everton collapses
-
'Humiliated' Aubameyang quits Gabon national team
-
Pacific islands to face food shortages over global warming: scientists
-
France sees limited economic hit from drought, heatwaves
-
Venice jury head Maggie Gyllenhaal questions lack of women directors
-
Bus crash in Egypt's Sinai kills 22, including 10 Jordanians
-
Stocks drop, bond yields rally on Mideast flare-up
-
UN says world must navigate 'reality' of 1.5C overshoot
-
China expands Egypt investments in first Xi visit in a decade
NYSE - LSE
RETRANSMISSION: MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank
GENEVAD, SE / ACCESS Newswire / March 19, 2026 / MindMaze Therapeutics Holding SA (SIX:MMTX) (the Company), a global leader in brain technology and precision neurotherapeutics, today announced that Baader Bank has initiated equity research coverage on the Company's shares.
Baader Bank has initiated coverage with a Buy recommendation and a target price of CHF 1.80 per share. This new coverage complements the existing research coverage provided by Edison Group, which currently values the Company at CHF 3.56 per share.
About MindMaze Therapeutics
MindMaze Therapeutics (SIX:MMTX) is a global leader in brain technology, dedicated to redefining the recovery trajectory for patients with neurological platform-based digital treatments. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to the home-based therapy. The Company's FDA-cleared and CE-marked neurotherapeutics are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson's disease, and other brain disorders. With a commitment to rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine.
For more information, visit www.mindmazetherapeutics.com.
Media & Investor Contacts
Investor Relations:
Jeremy Meinen, Chief Financial Officer
[email protected]
Media Inquiries:
VSC for MindMaze Therapeutics
[email protected]
DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, among others, business, economic, financial, regulatory, and competitive factors, as well as the Company's ability to execute its strategy. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE: MindMaze Therapeutics Holding SA
View the original press release on ACCESS Newswire
L.Miller--AMWN
